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Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical 
outcomes. CYP2C19 loss-of-function alleles play an important role in this response, but account for only a small 
proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics 
Consortium (ICPC) is to identify other genetic determinants of clopidogrel pharmacodynamics and clinical response. 
A genomewide association study (GWAS) was performed using DNA from 2,750 European ancestry individuals, using 
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adenosine diphosphate-induced platelet reactivity and major cardiovascular and cerebrovascular events as outcome 
parameters. GWAS for platelet reactivity revealed a strong signal for CYP2C19*2 (P value = 1.67e−33). After 
correction for CYP2C19*2 no other single-nucleotide polymorphism reached genomewide significance. GWAS for a 
combined clinical end point of cardiovascular death, myocardial infarction, or stroke (5.0% event rate), or a combined 
end point of cardiovascular death or myocardial infarction (4.7% event rate) showed no significant results, although 
in coronary artery disease, percutaneous coronary intervention, and acute coronary syndrome subgroups, mutations 
in SCOS5P1, CDC42BPA, and CTRAC1 showed genomewide significance (lowest P values: 1.07e−09, 4.53e−08, and 
2.60e−10, respectively). CYP2C19*2 is the strongest genetic determinant of on-clopidogrel platelet reactivity. We 
identified three novel associations in clinical outcome subgroups, suggestive for each of these outcomes.
Differential response to drug therapy is a common aspect of clin-
ical practice. The causes for interindividual heterogeneity in drug 
response include environmental, clinical (e.g., sex, age, disease se-
verity, drug-drug interactions, and adherence), as well as genetic 
factors. Personalized medicine based on these factors can improve 
patient care, in particular for drugs with a narrow therapeutic 
range or when insufficient drug efficacy or drug toxicity can have 
serious, potentially life-threatening consequences.1,2
The P2Y12 inhibiting drug clopidogrel is used in combination 
with the cyclooxygenase-1 inhibitor aspirin to prevent (recurrent) 
atherothrombotic events in patients with acute coronary syndrome 
(ACS), patients undergoing percutaneous coronary intervention 
(PCI), and in patients with stroke. Clopidogrel is a thienopyridine 
pro-drug that requires bioactivation mediated by hepatic CYP 
P450 enzymes to inhibit thrombogenesis by irreversibly binding 
the P2Y12 receptor on the surface of platelets.
3 There is a wide in-
terpatient variability in active metabolite levels and platelet reactiv-
ity, influenced by genetic and clinical variables, as well as drug-drug 
interactions.4–8 Both high “on-treatment platelet reactivity” as well 
as being a carrier of a CYP2C19 loss-of-function allele are related 
to a higher risk for (recurrent) atherothrombotic events.9–12
CYP2C19 variants, in particular the loss-of-function alleles 
CYP2C19*2 (rs4244285) and CYP2C19*3 (rs4986893), have 
previously been identified as the predominant genetic media-
tors of active metabolite levels and antiplatelet effect of clopido-
grel.5,13 A genomewide association study (GWAS) in a large Amish 
population indicated that ~ 70% of the variability in clopidogrel 
response may be due to genetic factors, with CYP2C19*2 being 
the strongest predictor, although this variant only accounted for 
~  12% of the overall variation in platelet reactivity.5 Combined 
with clinical factors (age, body mass index (BMI), and lipid lev-
els) ~  32% of the variation in pharmacodynamic clopidogrel re-
sponse could be explained. A study by Frelinger et al. conducted 
in 160 healthy subjects taking clopidogrel, showed that all known 
genetic and nongenetic factors together accounted for only 18% of 
the pharmacokinetic variation and 32–64% of clopidogrel phar-
macodynamic variation.14 In two studies with patients undergoing 
elective PCI, about 5% of the variability in platelet reactivity could 
be explained by CYP2C19 genotype, and about 11–20% when 
CYP2C19 genotype was combined with clinical variables.6,15 
Furthermore, clopidogrel nonresponders can be found not only 
among patients heterozygous or homozygous for CYP2C19 loss-
of-function (LOF) alleles, but also in patients without a LOF al-
lele.16 These data suggest that novel genetic variants for clopidogrel 
response remain to be discovered. The clinical utility of CYP2C19 
genotype-guided strategy for selection of P2Y12 inhibitors has been 
demonstrated in a number of recent studies.17,18 A risk score in-
cluding both clinical factors and CYP2C19 LOF alleles has also 
been developed to identify patients at higher risk for high platelet 
reactivity and adverse events (ABCD-GENE score).19 However, 
because LOF CYP2C19 alleles contribute to only a portion of the 
variability in the antiplatelet effect of clopidogrel, a strategy relying 
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Antiplatelet response to clopidogrel shows wide variation, 
and poor response is correlated with adverse clinical outcome. 
CYP2C19 loss-of-function alleles play an important role in this 
response, but additional genetic variants may remain unidentified.
WHAT QUESTION DID THIS STUDY ADDRESS?
 The aim of this study was to identify novel genetic loci as-
sociated with on-clopidogrel platelet reactivity and clinical 
outcome, by performing a genomewide association study of in-
dividuals of European ancestry treated with clopidogrel.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 A strong association was found for CYP2C19*2 and 
adenosine diphosphate stimulated platelet reactivity, while 
no single-nucleotide polymorphism reached genomewide sig-
nificance for major adverse cardiovascular event end points. 
Nevertheless, we observed significant novel hits in subgroup 
analyses for patients with coronary artery disease, acute coro-
nary syndrome, and who underwent percutaneous coronary 
intervention.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Our results support a CYP2C19 genotype guided anti-
platelet approach to tailoring of antiplatelet therapy, which 
has shown to be of clinical relevance. Nevertheless, a risk 
score containing other genetic, pharmacodynamic, and/or 
clinical risk factors might further improve assessment of re-
sponsiveness to clopidogrel and optimization of antiplatelet 
therapy.
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solely on the basis of well-known CYP2C19 LOF alleles may not 
be the most appropriate for a diverse patient population. A risk 
score encompassing multiple genetic variants, along with nonge-
netic factors would be more predictive and helpful in the clinical 
setting than a single factor alone.
The International Clopidogrel Pharmacogenomics Consortium 
(ICPC) aims to improve the understanding of clopidogrel pharma-
cogenomics by combining genetic, pharmacodynamic, and clinical 
outcome data of patients using clopidogrel.20,21 In this study, we 
present the largest GWAS performed to date on patients on clopi-
dogrel to identify novel genetic loci associated with on-clopidogrel 
platelet reactivity, major adverse cardiovascular events (MACE), 
and combined cardiac and cerebrovascular events (MACCE).
METHODS
The ICPC is an international effort led by the Pharmacogenomics 
Research Network (PGRN) and Pharmacogenomics Knowledgebase 
(PharmGKB).20 Based on the data published on www.clini caltr ials.gov 
as of June 2011, studies with at least 50 clopidogrel-treated patients po-
tentially containing genetic and platelet reactivity data were identified 
for participation. Lead investigators were invited to share DNA samples, 
platelet reactivity test results, patient characteristics, and cardiovascular 
outcomes to perform candidate gene and GWAS.22 To date, 17 sites from 
13 countries have joined the ICPC, contributing data representing 8,829 
clopidogrel-exposed patients. Of those patients, a DNA sample was avail-
able in 5,119 patients, a DNA sample and platelet reactivity data in 4,511 
patients, and in 2,844 patients a DNA sample, platelet reactivity data, 
and clinical outcome data were available. Platelet function was measured 
in patients on clopidogrel maintenance dose or after adequate loading 
dose, which was defined as at least 2 hours between a 600-mg clopidogrel 
loading dose and platelet function testing, 6 hours after 300-mg clopi-
dogrel loading dose, and 5  days after start of 75-mg maintenance dose 
without extra loading dose. Of these, 2,750 were of European ancestry in 
whom GWAS genotyping was performed. Each study in the ICPC was 
conducted with institutional review board approval at each respective 
data collection site and activities of the ICPC determined as exempt from 
institutional review board review by the University of Maryland under 
45 Code of Federal Regulations (CFR) 46.101(b).
DNA samples were made available for genotyping at RIKEN ( Japan). 
Genotyping was performed on the Illumina Human Omni express exome 
chip. Variants were called using Illumina Beadchip studio. This dataset 
consisted of 964,193 variants. We imputed the data to 1000 Genomes 
phase I reference panel using IMPUTE2. Prior to imputation, strand 
check and phasing were performed using SHAPEIT2. Imputations were 
performed following best practices guidelines, as previously published.23
Standard quality control measures were conducted using PLINK (ver-
sion 1.90).24 Sex check resulted in dropping 29 samples that were inferred 
as sex mismatches. We removed samples and markers that did not pass 
99% missingness thresholds. Variants that deviated from Hardy–Weinberg 
Equilibrium (P value = 1 × 10−7) were flagged. Relatedness among sam-
ples was tested using SNPrelate; one sample from each pair of related 
individuals at a kinship > 0.125 were excluded from the analysis.25 This 
resulted in removal of 20 additional samples. Last, principal component 
analysis was performed to check for ancestry. We calculated a total of 20 
principal components (PCs); PC1 and PC2 explained the most variance 
and, thus, were used as covariates in the analyses.
GWAS was performed for platelet reactivity and clinical outcomes. 
Because platelet reactivity was measured using different platelet function 
tests in each ICPC subcohort, measurements were standardized across 
these different tests using a priority system laid out by the Phenotype 
Subcommittee of the ICPC. Table S2 shows the unique number of pa-
tient samples assayed for each platelet function test. First, we validated the 
association of CYP2C19*2 (rs4244285) and CYP2C19*17(rs12248560) 
for different platelet reactivity assays used by ICPC sites (Table S1). 
Standardization measures were applied to maximize the number of pa-
tients with platelet function tests that were validated based on their as-
sociation with CYP2C19*2 and, thus, statistical power for GWAS. The 
prioritization was as follows: VASP assay > VerifyNow P2Y12 > adenosine 
diphosphate (ADP)-induced LTA (higher ADP concentration  >  lower 
ADP concentration)  >  other tests.20 For each subcohort, one platelet 
function test was chosen based on the highest-ranked assay measured at 
that site that maximized the sample size. A schematic of this is shown 
in Figure S1. Standardization of platelet reactivity phenotypes was per-
formed by calculating a Z-score within each study for use in analyses across 
studies, as previously reported.20,22 Each selected variable was then stan-
dardized with mean of 0 and SD of 1 while grouping by site and the se-
lected variable. Standardized platelet reactivity was used as a continuous 
response variable in our GWAS.
For the clinical outcomes, we evaluated several different phenotypes, 
including: (i) MACE: a combined end point consisting cardiovascular 
death and myocardial infarction; (ii) MACCE: a combined end point 
consisting of cardiovascular death, myocardial infarction, and stroke; and 
(iii) individual clinical end points: stent thrombosis, all-cause death, car-
diovascular death, myocardial infarction, stroke, revascularization, major 
bleeding, minor bleeding, and combined major and minor bleeding. 
Because of the heterogeneity of the database in diagnosis and risk profile, 
we also conducted the MACE, MACCE, and stent thrombosis analyses in 
overlapping subgroups with increasing atherothrombotic risk, including 
only patients with coronary artery disease, only patients who underwent 
PCI, and only patients with ACS.
Statistical analysis was performed using PLATO and PLINK software 
in which linear regression was used for quantitative phenotypes (standard-
ized ADP stimulated platelet reactivity phenotypes) and logistic regres-
sion for binary phenotypes (clinical outcome phenotypes).26,27 Variants 
with minor allele frequency > 0.0025 were tested. Approximately 5 mil-
lion (5,009,928) genotyped and imputed variants were evaluated for as-
sociation. For each analysis, Manhattan and quantile-quantile plots were 
generated to visualize the results. GWAS regression models were adjusted 
for age, sex, and the first 2 PCs (Text S1). In platelet reactivity analysis, we 
aimed to identify novel variants associated with the quantitative pheno-
type other than the known CYP2C19*2 variant (rs4244285) or variants 
in high linkage disequilibrium (LD) with the known variant. Thus, we 
conducted association testing where regression models were adjusted for 
CYP2C19*2 along with age, sex, and the first 2 PCs. We also performed 
a gene-based association test using the tool MAGMA as implemented 
in the web-based tool FUMA.28,29 FUMA uses GWAS summary statis-
tics to identify independent significant single-nucleotide polymorphisms 
(SNPs) and also independent lead SNPs where the LD r2 for each SNP in 
a genomic locus is < 0.1. MAGMA utilizes summary statistics from SNP-
based tests to map all SNPs to protein coding genes and then a gene-based 
test is performed to identify significance of the gene. Gene based P values 
are computed for all SNP mapping to protein coding genes. Functional 
annotation of SNPs is obtained by ANNOVAR in FUMA.30 The results 
from MAGMA analyses are shown in Manhattan plots simultaneously 
with SNP-based Manhattan plots for each phenotype.
SPSS (version 24; IBM, Armonk, NY) was used to analyze the correla-
tion between CYP2C19 variants and clinical outcome, using a two-tailed 
Pearson χ2 test and logistic regression for binary and categorical variables. 
To calculate the adjusted odds ratio, models were adjusted for age, sex, and 
study center. We did not adjust for other potential covariates, such as dia-
betes, smoking, etc., because of incomplete data across the ICPC sites; this 
would have resulted in losing patient-participants.
RESULTS
A total of 2,750 ICPC samples of European ancestry were available 
in this report. After quality control, a total of 2,592 samples were 
available for GWAS. Table 1 shows the baseline characteristics 
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of the participants included in the GWAS. We identify that 96% 
of the samples were prescribed aspirin and 86.2% samples in this 
study were currently using statins. In our data, we observed 39% of 
populations are carriers for alternate allele for CYP2C19*17 and 
31.2% population are carriers for CYP2C19*2 and *3 alleles.
Standardized ADP platelet reactivity GWAS
For the primary platelet reactivity phenotype, in models adjusted 
for age, sex, and principal components, we observed that the 
CYP2C18 locus (rs35835168, most significant P value = 3.51e−35) 
reached genomewide significance. Rs35835168 is in high LD with 
the known CYP2C19*2 locus rs4244285 (r2 = 0.88 and |D|’ = 1). 
Rs4244285 has been identified in previously published GWAS 
for association with response to clopidogrel therapy.5 No other 
loci in the single-SNP analyses reached genomewide significance 
(Figure 1a). The top 30 associations from GWAS are reported in 
Table S3. The results from the MAGMA analysis are shown in 
Figure 1b.29 Input SNPs were mapped to 17,964 protein coding 
genes in the MAGMA analyses, which identified 9 significant 
genes after using a multiple hypothesis correction P value thresh-
old of 2.75e−06 (0.05/17,964). Most genes observed from the 
gene-based analyses correspond to a genomic region on chromo-
some 10 (10:96098093-96990275), which encodes a CYPP-450 
gene cluster that includes CYP2C19, as shown in regional plot 
Figure 1c (lower panel). The SYNJ1 gene on chromosome 21 
was also identified as significant from the gene-based analyses (P 
value = 1.001e−06).
In an attempt to identify other variants associated with on-treat-
ment platelet reactivity, we repeated the GWAS, adjusting for 
CYP2C19*2. Figure 2a,b displays the results from SNP-based and 
gene-based analyses. Top 30 associations from GWAS are reported 
in Table S4. Based on the statistical test in FUMA (explained in 
the Methods section), 16 genomic risk loci consisting of top 17 
SNPs were identified. Figure 2c highlights lead genomic loci, the 
number of mapped genes for each loci, and also functional an-
notation of SNPs (and SNPs in LD) using ANNOVAR.30 With 
Table 1 Baseline characteristics for all study participants 
analyzed in the GWAS
n (%) or mean ± SD
Self-reported race white 2,592/2,592 (100.0)
Sex, male 1,996/2,592 (77.1)
Age, years 64.6 ± 11.2
BMI, kg/m2 27.8 ± 4.6
Diabetes mellitus 636/2,571 (24.7)
Current smoker 613/2,147 (28.6)
Hypercholesterolemia 1,259/1,951 (64.5)
LVEF < 35% 82/1,020 (8.0)
Aspirin use 2,482/2,585 (96.0)
Statin use 2,141/2,485 (86.2)
CYP2C19*2 and/or *3 allele 
carrier
812/2,600 (31.2)
CYP2C19*17 allele carrier 980/2,512 (39.0)
Coronary artery disease (indica-
tion for clopidogrel use)
2,509/2,592 (96.8)
PCI performed 2,065/2,492 (82.9)
Acute coronary syndrome 1,188/2,492 (47.7)
BMI, body mass index; GWAS, genomewide association study; LVEF, left 
ventricular ejection fraction; PCI, percutaneous coronary intervention.
Figure 1 Association results from analyses adjusted by age, sex and PCs (a) Single-nucleotide polymorphism (SNP)-based genomewide 
association study (GWAS) Manhattan plot where chromosome position is on x-axis and -log10 of association P value on y-axis (genomic 
inflaction factor = 1.01). (b) Gene-based GWAS Manhattan plot performed by MAGMA highlighting top 15 genes. (c) Regional plot for 
chromosome 10 highlighting lead SNP rs35835168. The first panel shows SNPs in linkage disequilibrium (LD) of any significant independent 
lead SNPs. LD range is represented based on color (blue to red). Second and third panels shows Combined Annotation Dependent Depletion 
(CADD) and Regulome DB scores, respectively, for only SNPs in LD with lead SNPs.
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adjustment for CYP2C19*2, no other SNPs reached the genome-
wide significance threshold (lowest P value = 1.59e−07). We ex-
plored further suggestively significant results (P value < 1.0e−05) 
to help elucidate the genetic architecture of platelet reactivity 
response phenotype (Table 2). At the CYP2C19 locus on chro-
mosome 10, variants in PLCE1 remained nominally associated 
Figure 2 Association results from analyses adjusted by age, sex, PCs and CYP2C19*2 variant (a) Single-nucleotide polymorphism (SNP)-based 
genomewide association study (GWAS) Manhattan plot where chromosome position is on x-axis and -log10 of association P value on y-axis 
(genomic inflation factor = 1.01). (b) Gene-based GWAS Manhattan plot of performed by MAGMA highlighting top 15 genes. (c) Summary of 
lead SNPs identified by the analyses; (d) functional annotation of lead SNPs and SNPs in linkage disequilibrium (LD) using ANNOVAR.
Table 2 Lead SNPs identified by platelet reactivity response GWAS, adjusted by age, sex, PC1, PC2, project site, and 
CYP2C19*2 locus
SNP Chromosome Position MAF Gene P value Beta SD IndSigSNPs
rs151216272 9 28118945 0.01 LINGO2 1.60E−07 −0.64 0.12 rs151216272
rs35464072 4 149326236 0.45 NR3C2 2.75E−07 0.14 0.03 rs35464072;
rs1546044;
rs13118022
rs74952072 6 166108326 0.04 GAPDHP72 1.47E−06 0.32 0.07 rs74952072
rs1516568 3 6949230 0.11 GRM7 2.92E−06 −0.2 0.04 rs1516568
rs57908830 22 27759178 0.03 MN1 2.99E−06 0.4 0.08 rs57908830
rs2479921 13 70749169 0.18 NA 3.42E−06 0.16 0.03 rs2479921
rs9399096 6 134740060 0.07 NA 3.59E−06 −0.25 0.05 rs9399096
rs7276140 21 34005200 0.44 SYNJ1 4.31E−06 −0.12 0.03 rs7276140
rs117956006 13 97918928 < 0.01 MBNL2 5.51E−06 1.19 0.26 rs117956006
rs1219603 10 36543314 0.15 NA 5.55E−06 0.18 0.04 rs1219603
rs61670395 18 40885561 0.06 NA 6.01E−06 −0.25 0.06 rs61670395;
rs113478533
rs76180455 10 95994508 0.02 PLCE1 7.01E−06 −0.4 0.09 rs76180455
rs10505836 12 19288508 0.16 PLEKHA5; 7.24E−06 0.17 0.04 rs10505836
SRSF11P1
rs142225302 14 97480714 0.02 NA 8.25E−06 0.5 0.11 rs142225302
rs148114323 5 162707344 0.01 NA 8.38E−06 −0.78 0.18 rs148114323
rs140497518 14 97483211 0.02 NA 8.83E−06 0.49 0.11 rs140497518
rs2473481 6 532089 0.21 EXOC2 9.74E−06 −0.15 0.03 rs2473481
SNP column represents top lead significant SNP and IndSigSNPs column list all independent significant SNPs in a genomic locus.
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with on-treatment platelet reactivity (lowest P value = 7.01e−06). 
Other top hits include association of rs151216272 mapping to 
LINGO2 on chromosome 9 (P value = 1.59e−07), which has been 
associated with BMI and neurotic behavior,31,32 and rs74952072 
in GAPDHP72 on chromosome 6 (P value  =  1.47e−06), which 
has been associated with blood pressure, insomnia, and blood urea 
nitrogen.33–36 Among the lead SNPs is a cluster of 3 variants in 
the NR3C2 (rs1546044, rs35464072, and rs13118022) on chro-
mosome 4, which have been previously associated with schizophre-
nia from GWAS,37 rs7276140 in SYNJ1 on chromosome 21 (P 
value = 4.31e−06) that has been linked with Parkinson’s disease,38 
and rs2473481 on chromosome 6 (P value  =  9.74e−06), which 
maps to the nearest gene RP1-20B11.2, has an expression quanti-
tative trait locus mapping to EXOC2, and was previously found to 
be associated with mean corpuscular hemoglobin.39
Clinical outcomes
Outcome data regarding the combined clinical end point where 
patients were followed for an average of 14 ± 11 months were avail-
able for 2,170 (MACE end point) and 1,447 (MACCE end point) 
patients, with an event rate of 4.7% and 5.0%, respectively. First, 
univariate and multivariate analyses were performed for the cor-
relation between the CYP2C19*2 allele and outcome (Table 3). 
For the MACE end point, there was a nonsignificant trend to-
ward a worse outcome for carriers of the CYP2C19*2 allele (5.8 
vs. 4.2%; adjusted odds ratio (OR) 1.31; 95% confidence interval 
(CI) 0.87–1.99; P value  =  0.20). This difference became more 
prominent in the subgroups with patients with higher thrombotic 
risk, in particular in patients with ACS who underwent PCI (8.3 
vs. 4.4%; adjusted OR 1.83; 95% CI 1.06–3.15; P value = 0.03). 
When the MACCE end point was analyzed, this association was 
not present. In addition, for the individual outcome events, in-
cluding bleeding end points, no statistically significant association 
was found in multivariate analysis (Table 3).
GWAS of the clinical outcome traits are shown in Figures 
S2–S4 and the top 30 associations are reported in Tables S5–S7. 
We did not find any genomewide significant associations with ei-
ther of the composite clinical outcomes or any of the individual 
clinical outcome variables. Among the marginally significant re-
sults in MACE was variant rs151062494 on chromosome 7 (P 






OR (95% CI) P value OR (95% CI) P value
All patients in GWAS MACE (n = 102/2,170) 5.8% vs. 4.2% 1.42 (0.94–2.14) 0.09 1.31 (0.87–1.99) 0.20
MACCE (n = 72/1,447) 4.4% vs. 5.2% 0.89 (0.49–1.43) 0.52 0.79 (0.46–1.37) 0.40
Individual end points:
All cause death 
(n = 72/2,580)
3.3% vs. 2.5% 1.33 (0.82–2.16) 0.25 1.24 (0.76–1.07) 0.39
Cardiovascular death 
(n = 40/2,492)
2.4% vs. 1.2% 1.99 (1.06–3.73) 0.028 1.82 (0.96–3.45) 0.065
Myocardial infarction 
(n = 83/2,254)
3.8% vs. 3.6% 1.06 (0.66–1.69) 0.82 0.99 (0.61–1.58) 0.95
Stroke (n = 21/1,838) 1.1% vs. 1.2% 0.95 (0.37–2.45) 0.91 0.88 (0.33–2.30) 0.79
Stent thrombosis 
(n = 37/2,579)
1.2% vs. 1.5% 0.81 (0.39–1.68) 0.57 0.79 (0.38–1.66) 0.54
Revascularization 
(n = 332/2,451)
12.4% vs. 14.1% 0.87 (0.67–1.12) 0.26 0.86 (0.66–1.13) 0.28
Major bleeding 
(n = 33/1,703)
1.8% vs. 2.0% 0.88 (0.41–1.91) 0.75 0.85 (0.39–1.86) 0.69
Minor bleeding 
(n = 61/996)
5.0% vs. 6.6% 0.75 (0.41–1.36) 0.34 0.76 (0.41–1.42) 0.39
Major + minor bleeding 
(n = 94/1,703)
4.7% vs. 5.8% 0.80 (0.50–1.28) 0.35 0.79 (0.49–1.29) 0.35
CAD subgroup MACE (n = 99/2,079) 6.1% vs. 4.1% 1.50 (0.99–2.27) 0.052 1.39 (0.92–2.11) 0.12
MACCE (n = 66/1,356) 4.5% vs. 5.0% 0.89 (0.51–1.55) 0.68 0.85 (0.48–1.50) 0.57
PCI subgroup MACE (n = 73/1,653) 5.9% vs. 3.7% 1.63 (1.01–2.62) 0.043 1.47 (0.90–2.39) 0.12
MACCE (n = 30/930) 2.6% vs. 3.5% 0.74 (0.31–1.75) 0.49 0.73 (0.30–1.76) 0.48
ACS subgroupb MACE (n = 58/1,017) 8.3% vs. 4.4% 1.97 (1.16–3.36) 0.011 1.83 (1.06–3.15) 0.030
MACCE (n = 15/459) 3.2% vs. 3.3% 0.98 (0.31–3.14) 0.98 1.00 (0.29–3.41) 1.00
ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval; GWAS, genomewide association study; MACCE, combined cardiovascular 
death, myocardial infarction, stroke; MACE, combined cardiovascular death, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.  
All values in bold are significant at the P < 0.05 level.
aAdjusted OR: adjusted for age, sex, and study center.  bAll patients with ACS underwent PCI.
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value = 4.10e−07), and for MACCE variant rs4782918 on chro-
mosome 16 in the WFDC1 gene (P value = 2.63e−06).
We also conducted GWAS for clinical outcomes among the sub-
groups of patients with coronary artery disease (n = 2,509), who un-
derwent PCI (n = 2,065), and with ACS (n = 1,188), reasoning that 
there might be stronger genetic determinants of on-treatment clinical 
outcomes in patients at higher risk for recurrent events. Genomewide 
significant results were obtained for MACE (in all subgroups) and 
stent thrombosis (in the subgroup of patients with coronary artery 
disease). These results are represented in a composite Manhattan 
plot shown in Figure 3. All other subgroups resulted in no genome-
wide significant results. Among the top hits in the coronary artery 
disease subgroup analyses are SNPs rs151062494 and rs115346894 
on chromosome 7, mapped to the nearest gene SOCS5P1, and chro-
mosome 1, mapped to the nearest gene CDC42BPA, respectively. 
SNPs mapping to gene SOCS5P1 are significant in coronary artery 
disease, ACS, and PCI subgroup analyses as well. Stent thrombo-
sis, coronary artery disease, and PCI subgroup analyses revealed an 
association in gene CTRAC1 (P value = 2.59e−10 and 7.91e−09, 
respectively). These results are reported in Table S8.
Finally, we reasoned that variants with suggestive associations 
with both on-treatment platelet reactivity and clinical events in 
the same expected direction may be more likely to represent true 
positive signals. We highlight clinical outcome analyses for variants 
that showed significant or suggestive association with on-treat-
ment platelet reactivity (P value < 10e−06) for analyses adjusted 
with CYP2C19*2 (Figure 4).
DISCUSSION
GWAS provide an agnostic approach to identifying genetic vari-
ants that influence human traits. We hypothesized that based 
on previous studies looking for the genetic factors’ association 
with response to clopidogrel, additional genetic variants remain 
unidentified and that these factors may be detected with larger 
sample sizes. As far as the authors are aware, our current study 
represents the largest GWAS for clopidogrel response published 
to date. We found CYP2C19*2 to have a statistically significant 
influence on platelet reactivity in patients using clopidogrel, as 
expected based on previous publications.9 However, no new ge-
netic variants reached genomewide significance for on-treatment 
platelet reactivity. Although there was a significant association 
between CYP2C19*2 and MACE in univariate and multivariate 
analyses in the patients with the highest ischemic risk (after PCI 
for ACS), no SNP reached genomewide significance for the clin-
ical end points in the main GWAS analyses using all clopidogrel 
treated patients in the dataset. These findings provide additional 
evidence that CYP2C19*2 is the single major genetic determinant 
of clopidogrel response in European ancestry individuals.
Two previous GWAS in the Amish population and one GWAS 
in Asians have been performed for clopidogrel response. First, 
Shuldiner et al. performed a GWAS in healthy Amish individu-
als and identified CYP2C19*2 as the only genomewide signifi-
cant association with on-treatment platelet reactivity.5 A second 
GWAS for the association with clopidogrel active metabolite 
levels, performed in 513 Amish individuals derived from the 
same study population, again showed CYP2C19*2 to have the 
strongest correlation with active metabolite levels.13 Two more 
loci were found to reach genomewide significance (rs187941554 
on chromosome 3p25 and rs80343429 on chromosome 17q11), 
of which the second SNP was also significantly associated with 
on-treatment platelet reactivity.13 Six additional loci showed sug-
gestive evidence of association (P value ≤ 1.0e−8), of which four 
Figure 3 Manhattan plot representing association results from subgroup analyses where patients with coronary artery disease (CAD), acute 
coronary syndrome (ACS), and percutaneous coronary intervention (PCI) were considered in the analyses as shown in each row. Columns 
represent phenotype tested (major adverse cardiac event (MACE), major adverse combined cardiac and cerebrovascular event (MACCE), 
and stent thrombosis). Each Manhattan plot represent chromosome position on x-axis and -log10 (P value) on y-axis. Red line represents 
genomewide significance threshold (5e−08).
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showed a significant association with on-treatment platelet reac-
tivity. In our study, we did not observe genomewide significance 
(defined as P value = 5e−08) for these variants or variants in LD 
with them. A smaller GWAS, published by Zhong et al., studied 
clopidogrel response in 115 Chinese patients with coronary ar-
tery disease. In this study, no single SNP reached genomewide sig-
nificance (P value < 7.11e−8) for platelet reactivity measured by 
VerifyNow (PRU cutoff > 208), although 125 SNPs in 25 genes 
showed suggestive evidence of association (P value < 1.0e−4).40 
Of those 125 SNPs, 27 were also associated with clopidogrel ac-
tive metabolite levels (P value < 0.01), of which 23 were within 
the HELLS-CYP2C18-CYP2C19 cluster, being in strong LD 
with one another and with CYP2C19*2. Multiple regression 
analysis showed that a combination of CYP2C19*2, rs2254638 
in N6AMT1, and rs2487032 in ABCA1 could explain 28.2% of 
antiplatelet response (10.9%, 14.8%, and 2.5% per SNP, respec-
tively), which increased to 37.7% when clinical factors (use of 
calcium channel blockers and sex) were added to the model. For 
active metabolite levels, CYP2C19*2 (explaining 16.3% of vari-
ability), rs2254638 in A6AMT1 (4.5%), rs12456693 in SLC4A3 
(2.7%), and age (4.8%) were significant predictors. When those 
SNPs were tested in a group of 299 patients undergoing PCI, 
with 1.5-year follow-up for MACE end points, a significant asso-
ciation was found for rs12913988 in ATP10A (P = 0.001; odds 
ratio (OR) for T allele 1.88; 95% CI 1.29–2.74) and a borderline 
significant result for rs2254638 in N6AMT1 (P value = 0.065; 
OR for the C allele 1.43; 95% CI 0.98–2.09). CYP2C19*2 was 
not associated with MACE end points in this cohort. In our 
GWAS analyses, the above reported genes were not found to be 
of genomewide significant association (P value < 5e−08) in the 
clinical outcomes’ analyses (both in all patients and in clinical 
subgroups of patients).
A recent article published by Lewis et al., presented a pharma-
cogenomic polygenic response score based on 31 candidate gene 
polymorphisms and tested in patient cohorts from the ICPC. Not 
all candidate gene variants presented in the above-mentioned ar-
ticle overlapped with our current analysis due to unavailability of 
same variants on genotyping platform or not passing all quality 
control filters from imputed data.22 Seven SNPs were identified 
to have an association with platelet reactivity, including SNPs 
in CYP2C19, CES1, CYP2B6, and CYP2C9. Although none 
of these SNPs were associated with cardiovascular events when 
analyzed separately, patients with an increasing number of risk 
alleles showed a higher cardiovascular event rate. Patients who 
carried eight or more risk alleles were significantly more likely to 
experience a cardiovascular event (OR 1.78; 95% CI 1.14–2.76; 
P  =  0.01) and cardiovascular death (OR 4.39; 95% CI 1.35–
14.27; n = 0.01) compared with patients who carried six or less of 
these alleles.
Significant results identified in our study are in close proximity 
and high LD with CYP2C19, suggesting an essential role in clopi-
dogrel metabolism. Gene-based analyses also identified several 
Figure 4 Scatter plot representing chr:pos on x-axis and -log10 (P value) on y-axis for results that are marginally significant in platelet 
reactivity response genomewide association study (GWAS), adjusted by age, sex, principal componenents (PCs), and CYP2C19*2 (platelet 
reactivity phenotype P value < 1e−05). Colored points correspond to P values from clinical outcome phenotypes major adverse cardiac event 
(MACE), major adverse combined cardiac and cerebrovascular event (MACCE), and stent thrombosis (ST). The orientation of triangle refers to 
positive (up) and negative (down) betas from regression analyses. ADP, adenosine diphosphate.
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significant genes not yet mentioned in previous studies that are 
close to the CYP2C19 cluster (such as HELLS, PLCE1, NOC3L, 
TBC1D12, CYP2C9, CYP2C8, and CYP2C18). MAGMA 
analyses also identified SYNJ1 as significant in this association. 
Mutations in SYNJ1 are linked to Parkinson’s disease, but its associ-
ation with platelet reactivity has not been previously described.41,42 
Regression models adjusted for CYP2C19*2 also demonstrated a 
suggestive association with SYNJ1, and for NR3C2, known to be 
associated with schizophrenia.37
There are some limitations to this study that are worth consid-
ering. First, the sample size was insufficient to detect rare variants, 
even those of moderately large effect sizes. Second, there may have 
been difficulty in imputing specific rare variants in the GWAS 
data. For example, the G143E CES1 variant (rs71647871) has an 
allele frequency of 0.016 and was found to be highly associated 
with on-treatment platelet reactivity in the candidate gene study 
by Lewis et al., as was discussed above, but this variant was not in-
cluded in our study (it was not genotyped and it did not impute 
with high quality).43 Exome and/or genome sequencing of large 
cohorts will be required to further understand rare variants such 
as this one. Third, for this GWAS, only patients from European 
ancestry were included. Thereby, variants that have low frequency 
in European ancestry populations but are present at a higher fre-
quency in other populations (e.g., CYP2C19*3 in Asian popu-
lations), would not have been detected in our GWAS. Fourth, 
the study sites used different methods to measure ADP-induced 
platelet reactivity as a marker for clopidogrel efficacy. Although a 
large GWAS using platelet reactivity measured with a single device 
would have been best, this was not possible across study sites of 
the ICPC and, thus, we applied a standardization approach across 
all studies in order to maximize sample size and power for GWAS 
discovery. We observed the CYP2C19*2 and *17 association as 
expected in assay stratified analyses as well as with the standard-
ized phenotype. We believe that this positive control demonstrates 
the validity of our phenotype harmonization. However, we ac-
knowledge that the correlation of platelet reactivity between dif-
ferent devices is limited and for some tests, laboratory dependent. 
Unfortunately, sample size varied markedly for each assay and there 
was insufficient power to perform GWAS for each individual test. 
In addition, platelet reactivity is likely influenced by timing after 
clopidogrel loading and dose. We believe medication compliance 
was not a major factor because all patients were tested shortly after 
clopidogrel initiation of a thrombotic event. Additionally, clinical 
factors, such as age, diabetes, smoking status, BMI, statins use, as-
pirin use, and drug-drug interactions, in addition to factors related 
to the testing method, like hematocrit levels and platelet, also play a 
role in influencing platelet reactivity.4,6,7,44,45 However, due to vari-
able missingness of data across sites, we were not able to adjust our 
analyses for these factors. These nongenetic factors may decrease 
the sensitivity of our GWAS to identify loci for platelet reactivity. 
Another potential limitation is that we could not evaluate whether 
aspirin had any effect in our study; a total of 96% patients in our 
cohort were taking low-dose aspirin.
With regard to clinical outcomes, the power to identify genome-
wide associations with individual clinical outcomes was limited 
due to the small number of outcome events. Thus, our analyses 
for clinical outcomes is highly exploratory and hypothesis gener-
ating. In addition, our dataset contains a patient population with 
relatively low risk for (recurrent) events, with most patients treated 
after elective PCI. This might explain the findings that although 
CYP2C19*2 has been linked to clinical outcomes in previous 
studies, we did not identify this signal in the GWAS performed 
here in the overall sample, but did detect nominal association of 
CYP2C19*2 with clinical outcomes in the subgroups at higher 
ischemic risk (in particular in patients after PCI for ACS). That 
said, several potential novel candidates were identified among the 
subgroup of samples with MACE or stent thrombosis outcomes 
(CDC42BPA, CTRAC1, and SOCS5P1). These associations are 
based on small sample sizes, however, and will need further replica-
tion in larger, well-powered studies.
To have an effect on everyday clinical practice, genetic determi-
nants affecting clopidogrel efficacy must demonstrate clinical util-
ity and be easily integrated into patient care. For the CYP2C19*2 
and *3 polymorphisms, point-of-care and laboratory-based testing 
is available, which makes it feasible to tailor antiplatelet therapy 
at the bedside.46–48 The recently published randomized, open-la-
bel, assessor-blinded CYP2C19 Genotype-Guided Antiplatelet 
Therapy in ST-Segment Elevation Myocardial Infarction 
Patients—Patient Outcome after Primary PCI (POPular 
Genetics) trial tested a strategy of CYP2C19-guided antiplatelet 
therapy in 2,488 patients with ST-segment elevation myocardial 
infarction undergoing primary PCI, prescribing ticagrelor or pra-
sugrel to CYP2C19*2 or *3 LOF allele carriers and clopidogrel to 
noncarriers, in comparison to a standard treatment arm in which 
all patients were prescribed ticagrelor or prasugrel.17 The study 
showed a significant lower event rate for bleeding events in the 
genotype-guided arm, without increase in thrombotic events. 
The randomized Tailored Antiplatelet Therapy Following PCI 
(TAILOR-PCI) trial, of which results are expected to be pub-
lished soon, uses a comparable strategy (prescribing ticagrelor in 
patients with a CYP2C19 LOF allele and clopidogrel in noncar-
riers), but in patients after PCI for stable coronary artery disease 
or ACS.18
When additional genetic determinants of clopidogrel response 
are identified, one could imagine the creation of a risk score com-
posed of several genetic variants, along with nongenetic factors that 
would be more predictive than single factors alone. Our GWAS, 
however, suggests that there are no additional common variants 
with an effect size as great as that of CYP2C19. Therefore, our re-
sults strengthen the strategy of POPular Genetics to use CYP2C19 
genotyping in clinical practice to optimize antiplatelet therapy. An 
example of a risk score using clinical risk factors and genetic vari-
ants is the recently published ABCD-GENE score, which shows a 
good predictive value for patients with high on-clopidogrel platelet 
reactivity and clinical outcome based on age, BMI, kidney failure, 
diabetes, and CYP2C19 genotype.19
Larger studies, studies in non-European ancestry populations, 
and/or sequencing efforts to identify rare variants not tagged by 
GWAS are directions of potential future research.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
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